DNA-Platinum Thin Films for Use in Chemoradiation Therapy Studies by Rezaee, Mohammad et al.
Hindawi Publishing Corporation
Bioinorganic Chemistry and Applications
Volume 2012, Article ID 923914, 9 pages
doi:10.1155/2012/923914
Research Article
DNA-Platinum Thin Films for Use in Chemoradiation
Therapy Studies
Mohammad Rezaee, Elahe Alizadeh, DarelHunting,and L´ eon Sanche
GroupeenSciencesdesRadiations,D´ epartmentdeM´ edecineNucl´ eaireetRadiobiologie,Facult´ edeM´ edecineetdesSciencesdelaSant´ e,
Universit´ e de Sherbrooke, Sherbrooke, QC, Canada J1H5N4
Correspondence should be addressed to Mohammad Rezaee, mohammad.rezaee@usherbrooke.ca
Received 8 July 2011; Accepted 3 August 2011
Academic Editor: Goran N. Kaluderovic
Copyright © 2012 Mohammad Rezaee et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Dry ﬁlms of platinum chemotherapeutic drugs covalently bound to plasmid DNA (Pt-DNA) represent a useful experimental
model to investigate direct eﬀects of radiation on DNA in close proximity to platinum chemotherapeutic agents, a situation of
considerable relevance to understand the mechanisms underlying concomitant chemoradiation therapy. In the present paper we
determine the optimum conditions for preparation of Pt-DNA ﬁlms for use in irradiation experiments. Incubation conditions for
DNA platination reactions have a substantial eﬀect on the structure of Pt-DNA in the ﬁlms. The quantity of Pt bound to DNA as
a function of incubation time and temperature is measured by inductively coupled plasma mass spectroscopy. Our experiments
indicate that chemical instability and damage to DNA in Pt-DNA samples increase when DNA platination occurs at 37
◦Cf o r2 4
hours, the condition which has been extensively used for in vitro studies. Platination of DNA for the formation of Pt-DNA ﬁlms is
optimalatroomtemperatureforreactiontimeslessthan2hours.ByincreasingtheconcentrationofPtcompoundsrelativetoDNA
and thus accelerating the rate of their mutual binding, it is possible to prepare Pt-DNA samples containing known concentrations
of Pt while reducing DNA degradation caused by more lengthy procedures.
1.Introduction
Clinical studies have shown that concomitanttreatment with
chemotherapeutic drugs and radiotherapy often leads to a
higher rate of survival and local tumor control compared
to nonsynchronous treatments [1, 2]. Platinum chemother-
apeutic drugs are commonly used in concurrent chemora-
diation therapy (CRT) for treatment of solid tumors [3].
Although it is clear that platinum drugs and radiation in
CRT modalities increase tumor cell killing, improve lo-
coregional control of tumors, and enhance patient survival
[4, 5], the optimum schedule of the combination and
the underlying mechanisms of their synergistic action have
not been yet deﬁned [6, 7]. Since DNA is the common
target of both radiation and platinum chemotherapeutic
agents, most studies have focused on the structural and
functionalalterationofDNAresultingfromthecombination
[8, 9]. One possible mechanism responsible for the observed
synergy is enhancement in immediate (secondary) species
induced by primary radiation in the vicinity of the binding
site of the platinum compounds (Pt compounds) to DNA
[10, 11]. The most abundant of these secondary species
are electrons with the most probable energy of 9-10eV
[12]. Studies on the interaction of secondary low energy
electrons (LEEs) with DNA have elucidated some of the
fundamental mechanisms leading to DNA damage [13].
However, owing to the short range (∼10nm) of LEE in
biological matters, such studies must be performed on very
thinDNAﬁlmsofsimilarthickness.Pt-DNAthinﬁlmscould
provide an experimental approach to investigate the direct
eﬀects of the secondary electrons and other short-range
particles(orsecondaryspecies)onDNAinthepresenceofPt
compounds. Such investigations could disclose mechanisms
underlying the synergistic eﬀect between the radiation and
the drug, which may have implications for the optimization
of protocols in CRT as well as in the design and development
of new chemotherapeutic and radiosensitizing drugs [14].2 Bioinorganic Chemistry and Applications
Dry thin ﬁlms of bacterial plasmid DNA in supercoiled
conformation are widely used in low-energy irradiations
with LEEs [15, 16], photons [17], and ions [18]. They pro-
vide a simple system to evaluate the direct interaction of
short-range radiations with DNA, despite the complexity of
the molecule. Although puriﬁed prokaryotic DNA diﬀers
from eukaryotic DNA in terms of supercoiling and the
presence of N6-methyladenine [19, 20], supercoiled plasmid
DNA oﬀers the advantage of very high sensitivity for the
detection of single- and double-strand breaks. One of the
main concerns with plasmid DNA ﬁlms is maintenance of
the DNA integrity during ﬁlm preparation [21]. When the
irradiation target is supercoiled DNA, the proportion of the
supercoiled conﬁguration is often used as a measure of DNA
integrity. The DNA molecule is very sensitive to conditions
such as temperature, humidity, and pH, hence, the DNA
ﬁlms must be prepared under well-controlled conditions to
minimize damage. The concentration of ions in the solution
of DNA has also a considerable inﬂuence in maintaining
the DNA during ﬁlm preparation [21, 22]. Furthermore,
the type of substrate on which DNA is deposited aﬀects
the integrity of the molecule. Among the various substrates
testedincludingtantalum(Ta),goldandgraphite,Tainduces
the least damage to DNA [23].
Pt compounds such as cisplatin and carboplatin bind
to the N7 atom of purine bases and produce the Pt-DNA
adductsincludingmainlyintrastrandcross-links,interstrand
cross-links, and monofunctional binding to guanine [24].
The adducts distort the DNA conformation and reduce the
structural stability of DNA [24, 25]. Moreover, DNA must
tolerate the incubation conditions required to react with
Pt compounds. In most in vitro studies, a DNA solution
is mixed with a solution of the Pt compounds at 37◦C
f o r2 4o r4 8h o u r s[ 26–30]. These conditions aﬀect the
integrity of the DNA as a result of depurination and
oxidation processes [31]. To maximize the amount of the Pt
compoundsboundtoDNAwhilekeepingtheDNAintact,all
parameters involved in the preparation of the ﬁlms must be
known and carefully controlled. In particular, experimental
conditions forthe reaction of Pt compounds withDNA must
b ed e t e r m i n e da sw e l la st h ee ﬀect of chemical binding of Pt
compounds on the stability of DNA.
In the present study, we investigate the parameters of the
Pt compounds and platination reactions on DNA integrity
in the preparation of cisplatin/DNA and carboplatin/DNA
ﬁlms. Optimum experimental conditions are determined to
retain a high proportion of the supercoiled form of plasmid
DNA in Pt-DNA ﬁlms.
2.ExperimentalSection
2.1. Preparation of Plasmid DNA. Plasmid DNA (pGEM-
3Zf(-), 3197 base pairs, ca. 1968966 amu per plasmid) was
extracted from Escherichia coli JM109 and puriﬁed with
a HiSpeed plasmid Maxi kit (QIAGEN) [32]. The puriﬁed
plasmid DNA consisted of 96% supercoiled, 2% cancate-
meric, and 2% nicked circular forms. The concentration of
DNA and the relative quantity of proteins in the plasmid
DNA solution was then calculated by measuring the ratio
of ultraviolet (UV) absorption of DNA and protein at
260nm and 280nm, respectively, with a Synergy HT-I spec-
trophotometer. The ratio was 1.98 which corresponds to a
purity greater than 85% [33]. The TE buﬀer (Tris-EDTA:
10mM–1mM) was separated from DNA by gel ﬁltration
with a Sephadex G-50 medium [34]. Thus the ﬁnal solution
consisted of DNA and ddH2O after the ﬁltration. To evaluate
the eﬀect of Tris on the binding of Pt compounds to DNA,
two diﬀerent groups of the DNA solutions were prepared. In
the ﬁrst group, Tris buﬀer was added to the DNA solution at
the ratio of the one tris molecule per nucleotide, and in the
second group, the DNA solution was prepared with ddH2O
alone. The DNA concentration was the same in both groups.
In each group, control samples were kept in the temperature
of −20◦C and quantiﬁed for the analysis of temperature
eﬀect on DNA.
2.2. Platination of Plasmid DNA. The Pt compounds, cis-
platin[cis-diamminedichloroplatinum(II)]andcarboplatin
[cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)],
were purchased from Sigma-Aldrich with a stated purity of
99.9% and ≥98%, respectively, and used without further
puriﬁcation. Their solutions were prepared in ddH2O in dif-
ferent concentrations based on their molar solubility. Reac-
tions of cisplatin and carboplatin with the DNA solutions
were performed under diverse experimental conditions.
Theseconsistedof(1)twodiﬀerentincubationtemperatures,
that is, 37◦Ca n d2 5 ◦C, (2) incubation times varying from
40 minutes to 24 hours, and (3) molar ratios between Pt
compounds and DNA varying from ratios 2:1 up to 200:1.
DNA platination reactions were performed in the dark to
inhibit photoaquation processes as aqueous solutions of
cisplatin and carboplatin are degraded via illumination, es-
pecially at wavelengths below 500nm [35, 36]. To terminate
the reactions after a given incubation time, the solutions
were passed through a gel ﬁltration medium packed into a
column. By the ﬁltration, the unbound Pt compounds, tris
molecules, and complexes of tris with Pt compounds were
separated from the Pt-DNA solutions. The solutions passed
through the homemade column packed with Sephadex-G50
gel on a glass bead bed. Sephadex G-50 is a suitable medium
for separation of the molecules having a molecular weight
larger than 3 ×104 gmol −1 from molecules with a molecular
weight smaller than 1500gmol−1.S u c hﬁ l t r a t i o ni se x p e c t e d
to produce clean solutions of Pt-DNA in ddH2Ob e c a u s e
the molecular weights of most undesired compounds and
complexes found in the solutions during platination have
the molecular weight smaller than 1500gmol−1.
2.3. Analysis of Platinum-DNA Binding. The concentration
of platinum in the solutions was measured by Elan DRC
II inductively coupled plasma mass spectroscopy (ICPMS,
fromPerkinElmer)whichhasbeenusedasasuitablemethod
for measurement of platinum in many biomedical appli-
cations [37, 38]. Additionally, three control samples con-
sisting of the Pt compounds dissolved in ddH2O at known
concentrations were also prepared to calibrate the ICPMSBioinorganic Chemistry and Applications 3
measurements of Pt-DNA samples. The DNA concentration
was measured by spectrophotometry. It was determined
from the optical density of DNA in solution measured by UV
absorption at a wavelength of 260nm. The concentration of
DNA was calculated from the reference optical density.
2.4. Preparation of Substrate, DNA, and Pt-DNA Films.
The DNA and Pt-DNA samples were deposited on a Ta
substrate. As shown in previous studies, the stability of
supercoiled plasmid DNA on Ta substrate is acceptable for
vacuum experiments on LEE-induced damage [23, 39]. The
Ta substrates in the current work consist of a thin ﬁlm of
Ta of thickness 450 ± 50nm evaporated onto a 0.4mm thick
silicon wafer. The surface of Ta was cleaned in pure ethanol
and ddH2O and dried with a ﬂow of dry nitrogen. Before
deposition of DNA and Pt-DNA samples onto the substrate,
the TE buﬀer was added to the DNA and Pt-DNA solutions
in the ratio of 3:1 (three organic ions per nucleotide). It
has been shown that this ratio protects the supercoiled form
of DNA during the process of DNA ﬁlm preparation [22].
The volumes of 7μL of the latter solutions of DNA and
Pt-DNA consisting of 250ng of each complex (DNA and
TE molecules as well as Pt-DNA and TE molecules) were
deposited onto the cleaned Ta surface. These quantities were
calculatedtoallowformationofaﬁve-monolayerﬁlm(about
10nm thickness) on the Ta substrate. Such a thickness has
been widely used in DNA-LEE experiments because it is
smallerthantheeﬀectiverangeoftheseelectrons(12–14nm)
for damaging DNA [40]. After freezing at −65◦Cf o r1 0
minutes in a glove box, the samples were lyophilized (freeze-
dried) under a pressure of 7mTorr by a hydrocarbon-free
turbomolecular pump for 2 hours.
2.5. Quantiﬁcation of the DNA and Pt-DNA Films. The DNA
andPt-DNAﬁlmswererecoveredfromtheTasubstrateswith
10μLo fT Eb u ﬀer. Comparison of the amount of recovered
DNA with the original DNA solution used for deposition
showed that approximately 98% of DNA was recovered
by the TE buﬀer. Quantiﬁcation of the diﬀerent structural
forms (e.g., supercoiled, nicked circular, linear, etc.) in the
DNA and Pt-DNA samples was performed by agarose gel
electrophoresis. The DNA samples and the agarose gels were
stained with SYBR Green I in the concentration of 100x
and 10000x, respectively. The samples were run on 1%
agarose gel in 1x TAE buﬀer at 100 volts for 7 minutes
following by 75 volts for 68 minutes (5Vcm−1). The gels
were then scanned by Typhoon-Trio laser scanner (from
GE Healthcare) adjusted for the blue ﬂuorescent mode at
an excitation wavelength of 488nm and ﬁlter type 520nm-
bandpass (520BP 40) in the normal sensitivity mode. Var-
ious forms of the DNA such as supercoiled, nicked circular,
etc.wereanalyzedbyImageQuant5.0(MolecularDynamics)
software. To accurately quantify, the binding efﬁciencies of
SYBR Green I for the same amount (75ng) of supercoiled
and linear DNA were measured, and then the correction
factor was determined. This factor arises from the weaker
binding of SYBR Green I to supercoiled DNA than to the
nicked circular and linear forms. A correction factor of 1.2
was obtained and applied to the quantiﬁcation of plasmid
DNA.
2.6. Statistical Analysis. OriginPro 8.1 SR1 (OriginLab Cor-
poration) software was used for statistical and mathematical
analysis. Paired t-test was the statistical test in which a
probability of 0.05 (5%) has been considered signiﬁcant.
3. Results and Discussion
3.1. Eﬀects of Incubation Temperature on DNA and Pt-DNA
Samples. Figure 1 (panels a and b) shows a comparison of
the percentage of supercoiled and nicked circular forms of
theDNAinthesamplesthathadbeenincubatedfor24hours
at three diﬀerent temperatures: −20◦C, 25◦C, and 37◦C. For
each incubation temperature, DNA analysis was performed
fortwotypesofsamples:(i)“DNAsolutions”,thatis,samples
obtained directly from the incubated solutions, and (ii)
“DNA ﬁlms”, that is, samples that had, after incubation, been
deposited and recovered from a Ta substrate. TE buﬀer was
added to the samples at a concentration corresponding to
three organic ions per nucleotide. Increasing the incubation
temperature resulted in a reduction of the supercoiled form
of DNA in both the solution and the ﬁlm samples. The
decrease is relatively small for the DNA solution samples;
the samples incubated at 25◦Ca n d3 7 ◦C show a decrease
of 3.8% and 9.5%, respectively, relative to that seen in the
sample maintained at −20◦C. At each temperature, the DNA
samples recovered from Ta show a greater loss of supercoiled
DNA than do the samples analyzed directly from solution. A
fraction of the supercoiled loss in the ﬁlm samples is related
to the damages which were induced during the incubation
in solution. Consequently, for DNA recovered from Ta, a
decreaseinthesupercoiledformwithincreasingtemperature
isalsoobserved,andthedecreaseisverylargeforthesamples
incubated at 37◦C. The decreases in the supercoiled form are
not statistically signiﬁcant among the DNA solution samples
with diﬀerent incubation temperatures (P value: 0.314,
0.106). However, the diﬀerence is statistically signiﬁcant
between the DNA ﬁlm samples incubated at 37◦C and the
DNA ﬁlms from samples incubated at 25◦Ca n d−20◦C( P
value: 0.012 and 0.009). Additionally, there is no signiﬁcant
diﬀerence between the DNA ﬁlms incubated at 25◦Ca n d
−20◦C( P value: 0.136).
As expected, there are enhancements in the formation
of the nicked circular form with increasing incubation
temperature. The increase is small except for the DNA ﬁlm
samples which were incubated at 37◦C. In these samples
the nicked circular form increases by factors of 3.7 and 3.4
compared to those kept at −20◦Ca n d2 5 ◦C, respectively.
These diﬀerences are statistically signiﬁcant (P value: 0.02
and 0.011). The high proportion of the nicked circular form
in the DNA recovered from ﬁlms introduces considerable
inaccuracy in the evaluation of radiation-induced DNA
damage.
In vitro studies have shown that heat can induce various
types of DNA damage such as depurination and guanine4 Bioinorganic Chemistry and Applications
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Figure 1: Comparison of the percentages of DNA supercoiled (a), DNA nicked circular (b), and Pt-DNA supercoiled (c) forms in the
solution and ﬁlm samples after incubation at −20◦C, 25◦C, and 37◦C for 24 hours. Data in (a)–(c) are means from three independent
experiments; three samples at each temperature are analyzed in each experiment; error bars show standard deviations. ∗indicates P value
>0.05, ∗∗indicates P value <0.05.
oxidation mediated by reactive oxygen species (ROS) [31,
41]. Reaction rate constants for formation of 8-oxoguanine
and guanine depurination at 37◦Ca r e4 .7 × 10
−10 s−1 and
1.3 × 10
−9 s−1 in DNA solutions, respectively [41]. In our
experiment, each plasmid sample contained 0.065pmole of
DNA bases in a volume of 7μL. After a 24-hour incubation
of the plasmid DNA at 37◦C, we can estimate that approx-
imately 7% and 18% of the plasmid contain 8-oxoguanine
molecules or have undergone guanine depurination, respec-
tively. Such DNA molecules are more susceptible to strand
breakage than the original DNA. Furthermore, evacuation
and lyophilisation during ﬁlm preparation induce physical
stress and can damage DNA [21]. Therefore, the DNA mol-
ecules,whichhavebeenkeptat37◦Cfor24hoursormore,do
not have suﬃcient structural stability to tolerate the process
of ﬁlm preparation. Our results suggest that the samples
incubated at 37◦C are more sensitive and vulnerable to the
ﬁlm preparation and recovery processes than DNA samples
incubated at 25◦Ca n d−20◦C.
Figure 1(c) shows the comparison of the percentage
concentration of supercoiled forms in samples of cisplatin-
DNA complexes incubated at 25◦Ca n d3 7 ◦C for 24 hours.Bioinorganic Chemistry and Applications 5
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Figure 2: Kinetics of binding of Pt compounds to plasmid DNA. The Pt compounds are: (a) cisplatin with the initial ratios in the solution
of 20:1, (b) 200:1, and (c) carboplatin with the initial ratios of 40:1 and (d) 200:1. The curves show the quantity of bound Pt compounds
per DNA molecule at diﬀerent incubation times at 25◦C. Data in (a)–(d) are means from three measurements; error bars show standard
deviations. The continuous black lines are exponential ﬁts to the data.
Again, the analyses were performed for two groups of
samples: (i) Pt-DNA solutions and (ii) Pt-DNA ﬁlms on a Ta
substrate. In the solution and ﬁlm samples, the proportion
of the supercoiled form of Pt-DNA is less than those for
DNA alone. The molar ratio of cisplatin to DNA in the
solutions was 2:1. TE buﬀer was added to the samples
in the concentration of three organic ions per nucleotide.
Predictably, in both samples the supercoiled form of DNA
decreased when the incubation temperature increased. The
decrease is small (4.2%) in the samples of Pt-DNA solution.
In contrast, there is a large decrease in the supercoiled form
of the Pt-DNA ﬁlm samples (20.5%). Statistical analysis
also showed that the decrease is signiﬁcantly diﬀerent for
the Pt-DNA ﬁlms with diﬀerent incubation temperatures
(P value: 0.0049). According to our results, the incubation
temperature during preparation of the Pt-DNA solution is
a substantial factor in determining the composition of Pt-
DNAﬁlmsonTasubstrateforuseinirradiationexperiments.
Moreover, the results suggest that a ﬁlm composed of
cisplatin-DNA complexes with a high proportion of intact
DNA molecules (supercoiled form) on a Ta substrate can be
obtained when DNA platination occurs at 25◦C.
3.2. Kinetics of Binding Pt Compounds to DNA. Following
platination at 25◦C, DNA has much less damage during the
process of deposition and recovery from the Ta substrate.
However, the DNA platination reaction proceeds with a
slower rate. Increasing the concentration of the Pt com-
pounds can compensate for this lower rate. Figure 2 shows6 Bioinorganic Chemistry and Applications
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the ratios of bound Pt-compound to DNA for diﬀerent
incubation times at 25◦C when the initial concentration
ratios of Pt compounds to DNA in solution are 200:1, 40:1,
and 20:1. The solution consists of plasmid DNA, cisplatin
or carboplatin, and tris with the ratio of 1:1 nucleotide.
This amount of tris was considered as the minimum amount
of buﬀer which can preserve the stability of DNA during
the preparation process. It is clearly seen that the binding
kinetics of cisplatin and carboplatin to DNA are similar and
exhibit exponential behavior. These curves generally reach
saturation prior to 8 hours and show a linear behaviour
prior to 2 hours. For the initial concentration ratio of 200
cisplatin molecules per DNA, it is possible to have Pt-DNA
samples with the ratios of bound cisplatin to DNA from
16:1 to 37:1 in 40-minute to 120-minute incubation times,
respectively.Forthesameincubationtimes,theratiosare2:1
and 3:1 when the initial ratio of cisplatin to DNA decreases
an order of magnitude (20:1). The results demonstrate that
various ratios of bound cisplatin or carboplatin to DNA can
be obtained in the incubation times of less than 2 hours by
increasing the initial concentration of the Pt compounds.
Since the kinetics curves obey a linear ﬁt for these incubation
times, it is possible to simply extrapolate a variety of Pt-DNA
ratios from this part of the curves.
Since Pt compounds can react with most buﬀers [42],
their concentration is also a relevant parameter in the DNA
platination process (i.e., buﬀers compete with DNA for
binding Pt compounds). Tris is widely used as a buﬀer, es-
pecially for solutions of nucleic acids. It also reacts with
Pt compounds to produce cis-[Pt(NH3)2(N-Tris)(OH)]+
and cis-[Pt(NH3)2(N,O-TrisH−1)]+ [43]. The bar graphs in
Figure 3 show a comparison of bound Pt compounds to
DNA ratios for three diﬀerent incubation times at 25◦C
for two diﬀerent solutions: (i) a mixture of DNA, cisplatin,
and ddH2O, and (ii) a mixture of DNA, cisplatin, ddH2O,
and tris with the concentration ratio of 1:1 nucleotide. The
initial concentration ratio of cisplatin to the DNA was 20:1
in the solutions. The results demonstrate that the ratio of
bound cisplatin to the DNA is more than double when the
platination reaction occurs in a ddH2O solution without tris
molecules.
3.3. Eﬀects of Incubation Time on DNA and Pt-DNA Films.
The bar graphs in Figure 4 show a comparison of the
percentage of supercoiled DNA and Pt-DNA samples that
were incubated at 25◦C for 2, 4, and 8 hours. The analyses
wereperformedforsamples thathadbeen recovered(i)from
solution, immediately after incubation (Figure 4(a)), and
(ii) from ﬁlms deposited on Ta (Figure 4(b)). The Pt-DNA
samples were prepared with either cisplatin or carboplatin.
The initial concentration ratio of the Pt compounds to DNA
was 200:1 and that of the TE buﬀer was three organic
ions per nucleotide. As seen from Figure 4, more than 90
percent of the DNA, in samples incubated for 2 hours, is in
the supercoiled form. The proportion of supercoiled form
decreases when the samples are incubated for 4 hours or
more. The decrease is statistically signiﬁcant in all samples
except for the pure DNA solution sample. As might be
expected, the decrease is greater in Pt-DNA ﬁlms than in
DNA samples. Thus, it is possible to prepare Pt-DNA ﬁlms
with a high proportion of supercoiled DNA at various
ratios of bound Pt to DNA, by mixing DNA with high
concentrations of Pt-compound solution and restricting the
length of the incubation to less than 2 hours, as long as the
incubation temperature does not exceed 25◦C.
3.4. Eﬀects of Bound Pt to DNA on Pt-DNA Samples Analysis.
The distortion of the DNA structure resulting from the
formation of Pt-DNA cross-links must be considered in
quantiﬁcation methods such as electrophoresis. Figure 5(a)
shows the migration of diﬀerent forms of cisplatin-DNA
in the electrophoresis gel. The mobility of the nicked cir-
cular, cancatemeric, and supercoiled bands is changed with
increasing numbers of bound Pt molecules per nucleotide
(Rb). The change is due to distortion of the diﬀerent forms
of DNA by cisplatin since Pt-DNA crosslinks are known to
cause conformational changes in DNA including shortening
(bending) and unwinding [44, 45]. The distortion becomes
greater as a function of the quantity of bound Pt molecules.
Figure 5 shows the dependence of the mobility of the super-
coiled, nicked circular, and cancatemeric forms of cisplatin-
DNA samples as a function of the ratio Rb in a 1% agarose
gel. The mobility of each form of Pt-DNA is normalized to
the same form of an unmodiﬁed DNA sample (Figure 5(b)).
As seen from Figure 5(b), the migration of the nicked
circular and supercoiled conﬁgurations generally increases
with rising Rb. However, the mobility of the nicked circular
form increases with a faster rate than that of the supercoiledBioinorganic Chemistry and Applications 7
78
80
82
84
86
88
90
92
94
96
∗∗
∗∗
Incubation time (hours)
DNA
Cisplatin-DNA
Carboplatin-DNA
2h 4h 8h
∗
S
u
p
e
r
c
o
i
l
e
d
f
o
r
m
(
%
)
(a)
∗∗
∗∗
∗
78
80
82
84
86
88
90
92
94
96
Incubation time (hours)
DNA
Cisplatin-DNA
Carboplatin-DNA
2h 4h 8h
S
u
p
e
r
c
o
i
l
e
d
f
o
r
m
(
%
)
(b)
Figure 4: Comparison of the percentages of supercoiled forms in the samples of DNA, cisplatin-DNA, and carboplatin-DNA (a) in solution,
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Figure 5: Mobility of cisplatin-DNA molecules in agarose gel. (a) Migration of the diﬀerent conﬁgurations of cisplatin-DNA molecules
separated by electrophoresis. Lane 1 is for a DNA sample and lanes 2–5 are for cisplatin-DNA samples with the number of bound cisplatin
molecules per nucleotide, Rb, of 0.0057, 0.008, 0.0091, and 0.0219, respectively. (b) Normalized mobility of the nicked circular, supercoiled,
and cancatemeric forms of Pt-DNA samples at diﬀerent Rb in gel electrophoresis.
form. Mobility of the cancatemeric conﬁguration decreases
with rising in Rb up to 0.009 and then increases for higher
Rb.
Since the number of Pt molecules per plasmid probably
represents a Poisson distribution for each Pt-DNA ratio, this
would be expected to reduce the resolution of the agarose
gels by increasing the dispersion within each band (i.e.,
the band width). The linear plasmid band lies between the
nicked circular and cancatemeric bands; thus an increase in
band width could hinder precise quantiﬁcation of the linear8 Bioinorganic Chemistry and Applications
band which usually is weaker than the others. Furthermore,
the nicked circular and cancatemeric bands merge owing to
increased band width and form one band at Rb = 0.022. Our
results show that the mobility changes are substantial for Rb
greater than 0.005.
4. Conclusion
Thin ﬁlms of platinum-DNA adducts can be considered
as useful models in irradiation experiments to study the
molecular mechanisms of radiosensitization which underlie
concomitant chemoradiation therapy. We have investigated
the optimum experimental conditions to prepare dry thin
ﬁlms of Pt compounds bound to plasmid DNA on a Ta
substrate. Incubation conditions in DNA platination re-
actions have substantial eﬀects on the stability of Pt-DNA,
particularly in the thin ﬁlm samples preparation. In most
in vitro experiments, reaction of Pt compounds with DNA
solutions has been performed at 37◦C for incubation times
varying from 24 to 48 hours. However, our results show
that these conditions can induce damage to the DNA
and highly sensitize them to manipulations required to
form thin ﬁlms and recover DNA from the Ta substrate.
The concentration of intact DNA increases signiﬁcantly in
the ﬁlm samples when the incubation temperature during
reaction with the Pt is reduced to 25◦C and the time of
incubation is 2 hours. By increasing the concentration of
the Pt compounds, it is possible to compensate for the
r e d u c e dr e a c t i o nr a t ea tl o w e rt e m p e r a t u r e .H i g hl e v e l so f
plasmid platination however aﬀect the quantiﬁcation of Pt-
DNA samples in agarose gel electrophoresis, because Pt-
DNA adducts distort the conformation of DNA molecules.
Therefore, the optimum condition is obtained from an
equilibrium between temperature, time, and Pt compounds
concentration during the DNA platination reaction.
By recording the kinetics of binding Pt compounds to
DNA, it is possible to extrapolate diﬀerent Pt-DNA ratios
from the kinetics curves. We have found that the proportion
of supercoiled DNA is more than 90% in the Pt-DNA ﬁlm
when the DNA platination reaction is performed at 25◦Cf o r
less than 2 hours in solutions containing the Pt compound
with quantities of less than 3 × 10
−2 Pt molecules per
nucleotide and the minimum concentration of Tris buﬀer
(one tris molecule per nucleotide). Under these conditions,
agarose gel electrophoresis is an accurate method for quan-
tiﬁcation of DNA damage. We have also determined that the
maximum number of bound Pt-compound per nucleotide
is about 5 × 10
−3 under our optimum conditions. This
ratio is an order of magnitude higher than those found in
biological studies and clinical applications [46]. These high
ratios, however, are useful for in vitro mechanistic studies in
which substantial quantities of product are required. Hence,
we have found that by adjusting the initial concentration of
Pt compounds in solution, Pt-DNA ﬁlms having a known
controlled ratio of platinum chemotherapeutic agents to
DNA can be obtained while maintaining DNA integrity.
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